logo
Sign in

Altor BioScience, LLC

MIRAMAR, FL · Biotech · Acquired

ALT-803, an IL-15 superagonist-receptor fusion protein therapeutic for intravesical immunotherapy of bladder cancer

Claim this profile

Follows are private to you and power your alerts

Updated · altorbioscience.com

Sector
Biotech
Headquarters
MIRAMAR, FL
Latest Form D
$30.3M, Mar 2017
Total capital
$87.1M
Federal grants
$11.2M
9 awards · 2015–2019
Rank in peer group#170 of 514
Private capital raised
$75.9M
9 Form D · last Mar 2017
115 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
27
13 pending · first 2021
Rank in peer group#3 of 514

Capital timeline

200920112013201520172019FEDERAL ↑EQUITY ↓Cumulative $87.1M$1.9M$966K$3M$1.0M$1.0M$1.0M5th Form D$6.2M7th Form D$10.7M9th Form D$30.3M
200920112013201520172019FEDERAL ↑EQUITY ↓Cumulative $87.1M$1.9M$3M$1.0M9th Form D$30.3M

Latest events

  • Federal grantHealth and Human S · Phase II · Novel IL-15 Superagonist Therapy for Bladder Cancer$1.0M
  • Federal grantHealth and Human S · Phase II · Novel IL-15 Superagonist Therapy for Bladder Cancer$1.0M
  • Federal grantHealth and Human S · Phase II · Novel IL-15 Superagonist Therapy for Bladder Cancer$1.0M
  • Federal grantHealth and Human S · Phase II · Novel IL-15 Superagonist Therapy for Bladder Cancer$3M
  • Private capital raisedForm D · SEC · 9th filing$30.3M
  • Federal grantHealth and Human S · Phase II · Combination Immunotherapy of a Novel Superagonist IL-15 Complex and Anti-CD20 Antibody for Indolent Non-Hodgkin Lymphoma$966K
  • Private capital raisedForm D · SEC · 8th filing$20M
  • Private capital raisedForm D · SEC · 7th filing$10.7M
  • Private capital raisedForm D · SEC · 6th filing$5.5M
  • Private capital raisedForm D · SEC · 5th filing$6.2M
  • Private capital raisedForm D · SEC · 4th filing$1.4M
  • Private capital raisedForm D · SEC · 3rd filing$250K
  • Private capital raisedForm D · SEC · 2nd filing$322K
  • Private capital raisedForm D · SEC · 1st filing$1.2M
Show 4 earlier federal awards
  • Federal grantHealth and Human S · Phase II · Combination Immunotherapy of a Novel Superagonist IL-15 Complex and Anti-CD20 Antibody for Indolent Non-Hodgkin Lymphoma$1.9M
  • Federal grantHealth and Human S · Phase II · Combination Immunotherapy of a Novel Superagonist IL-15 Complex and Anti-CD20 Antibody for Indolent Non-Hodgkin Lymphoma$962K
  • Federal grantHealth and Human S · Phase II · Novel IL-15 Superagonist Therapy for Bladder Cancer$598K
  • Federal grantHealth and Human S · Phase II · IL-15 Superagonist Complex as an Immunotherapeutic for Multiple Myeloma$750K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

  • Federal grants#170 · top 33%
  • Granted patents#3 · top 1%
  • Linked publications#16 · top 3%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Hing C. WongResearcherExecutive Officer, DirectorLinked by 3 patents · $5.2M in grants as PI
  • Peter C. RhodeResearcherExecutive OfficerLinked by $1.0M in grants as PI
  • Adam Boydon WaldmanDirectorNamed in SEC Form D filings
  • Adam C. Waldman, J.D.DirectorNamed in SEC Form D filings
  • Bee-Yau C. HuangExecutive OfficerNamed in SEC Form D filings
  • C. Boyden GrayDirectorNamed in SEC Form D filings
Show all 9 people
  • Fred C. MiddletonDirectorNamed in SEC Form D filings
  • Patrick Soon-ShiongDirectorNamed in SEC Form D filings
  • Rick S. GreeneExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 27 granted of 40
  • PendingIL-15-BASED Molecules And Methods Of Use ThereofUSPTOApplication 19672282
  • PendingIL-15-BASED Molecules And Methods Of Use ThereofUSPTOApplication 19388693
  • PendingMultimeric IL-15 Soluble Fusion Molecules And Methods Of Making And Using SameUSPTOApplication 19248938
Show all 40 patent records

Recent research by its founders

  • IL-7/IL-15/IL-21 cytokine-fusion scaffold generates highly functional CAR T cells enriched in long-lived T memory stem cells20261 cites
  • Abstract 1629: An innovative approach to improve bispecific T-cell engagers for solid tumor therapy20260 cites
  • 0054 Treg-targeted therapies restrain disease in a murine model of alopecia areata20250 cites

Related companies, and why

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .